Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy

Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1....

Full description

Bibliographic Details
Main Authors: Weronika Gawęda, Marek Pruszyński, Edyta Cędrowska, Magdalena Rodak, Agnieszka Majkowska-Pilip, Damian Gaweł, Frank Bruchertseifer, Alfred Morgenstern, Aleksander Bilewicz
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Nanomaterials
Subjects:
Online Access:https://www.mdpi.com/2079-4991/10/10/2067
id doaj-e5b1ab7c4e4d48a585d422d27ca7575b
record_format Article
spelling doaj-e5b1ab7c4e4d48a585d422d27ca7575b2020-11-25T03:44:29ZengMDPI AGNanomaterials2079-49912020-10-01102067206710.3390/nano10102067Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha RadioimmunotherapyWeronika Gawęda0Marek Pruszyński1Edyta Cędrowska2Magdalena Rodak3Agnieszka Majkowska-Pilip4Damian Gaweł5Frank Bruchertseifer6Alfred Morgenstern7Aleksander Bilewicz8Institute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandDepartment of Immunohematology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, PolandEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, 76125 Karlsruhe, GermanyEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, 76125 Karlsruhe, GermanyInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandBarium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin<sup>®</sup>). Thermogravimetric analysis and radiometric method with the use of [<sup>131</sup>I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained <sup>223</sup>Ra (>98%) and about 96% of <sup>211</sup>Bi and 94% of <sup>211</sup>Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.https://www.mdpi.com/2079-4991/10/10/2067alpha radioimmunotherapyradium-223barium ferrite
collection DOAJ
language English
format Article
sources DOAJ
author Weronika Gawęda
Marek Pruszyński
Edyta Cędrowska
Magdalena Rodak
Agnieszka Majkowska-Pilip
Damian Gaweł
Frank Bruchertseifer
Alfred Morgenstern
Aleksander Bilewicz
spellingShingle Weronika Gawęda
Marek Pruszyński
Edyta Cędrowska
Magdalena Rodak
Agnieszka Majkowska-Pilip
Damian Gaweł
Frank Bruchertseifer
Alfred Morgenstern
Aleksander Bilewicz
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
Nanomaterials
alpha radioimmunotherapy
radium-223
barium ferrite
author_facet Weronika Gawęda
Marek Pruszyński
Edyta Cędrowska
Magdalena Rodak
Agnieszka Majkowska-Pilip
Damian Gaweł
Frank Bruchertseifer
Alfred Morgenstern
Aleksander Bilewicz
author_sort Weronika Gawęda
title Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
title_short Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
title_full Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
title_fullStr Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
title_full_unstemmed Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
title_sort trastuzumab modified barium ferrite magnetic nanoparticles labeled with radium-223: a new potential radiobioconjugate for alpha radioimmunotherapy
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2020-10-01
description Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin<sup>®</sup>). Thermogravimetric analysis and radiometric method with the use of [<sup>131</sup>I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained <sup>223</sup>Ra (>98%) and about 96% of <sup>211</sup>Bi and 94% of <sup>211</sup>Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
topic alpha radioimmunotherapy
radium-223
barium ferrite
url https://www.mdpi.com/2079-4991/10/10/2067
work_keys_str_mv AT weronikagaweda trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT marekpruszynski trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT edytacedrowska trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT magdalenarodak trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT agnieszkamajkowskapilip trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT damiangaweł trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT frankbruchertseifer trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT alfredmorgenstern trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
AT aleksanderbilewicz trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy
_version_ 1724514659732553728